Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular CarcinomaRiad Salem, Robert J. Lewandowski, Mary F. Mulcahy et al.|Gastroenterology|2016Cited by 686
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experienceRiad Salem, Robert J. Lewandowski, Ahmed Gabr et al.|Hepatology|2017Cited by 235
Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular CarcinomaRyan Hickey, Riad Salem, S. Mouli et al.|Journal of Vascular and Interventional Radiology|2016Cited by 72